4 results on '"Fullerton, Sonia"'
Search Results
2. Daily Subcutaneous Parecoxib Injection for Cancer Pain: An Open Label Pilot Study.
- Author
-
Kenner, David J., Bhagat, Sandeep, and Fullerton, Sonia L.
- Subjects
- *
ACADEMIC medical centers , *SUBCUTANEOUS injections , *ANALYSIS of variance , *BONES , *CANCER pain , *NONSTEROIDAL anti-inflammatory agents , *PATIENT satisfaction , *SCALE analysis (Psychology) , *STATISTICS , *CYCLOOXYGENASE 2 , *PILOT projects , *DATA analysis , *TREATMENT effectiveness , *REPEATED measures design , *DATA analysis software , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background: Nonsteroidal anti-inflammatory analgesics (NSAIDs) are useful in cancer pain but the specific use of subcutaneous parecoxib has not been previously reported. Objective: This pilot study aimed to establish the efficacy and side effect profile of short-term sequential single daily dose subcutaneous parecoxib sodium in patients with severe cancer bone pain. Methods: Nineteen hospitalized patients with advanced cancer and uncontrolled malignant bone pain (9 males, 10 females) received 24 courses of one, two, or three days sequential therapy with 'off-label' daily subcutaneous parecoxib. All patients were receiving opioid therapy; the median baseline daily oral equivalent dose (OED) of morphine was 180 mg. Pain was assessed at baseline, 24 hours, 48 hours, and 72 hours. Pain scores as assessed on an 11-point numeric pain rating scale (NPRS), any side effects including subcutaneous site reactions, as well as patient satisfaction rating with analgesia were recorded. A clinically significant decrease in pain scores was defined as a reduction of two or more points on the NPRS. Results: Median pain score of all patient treatments decreased from 7 to 4.5 at 24 hours ( p<0.001) and 4.0 at 48 hours. A response was seen in 17 (71%) of the 24 treatments at 24 hours. There was no difference between median negative change in pain scores in 19 (79%) treatments where pain was either strongly movement related, or in 22 (94%) treatments where local bone tenderness was more pronounced. No major side effects were observed during treatment. One patient died from pulmonary embolism after cessation of concurrent prophylactic low molecular weight heparin prior to staging liver biopsy. Subcutaneous site reactions occurred in 2 (8%) treatments and were mild and self limiting. Conclusions: Short-term daily subcutaneous parecoxib injection was effective for malignant bone pain when added to existing analgesic therapy and was well tolerated. Further research is warranted into the short-term use of parecoxib in hospitalized patients with intractable malignant bone pain. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Subcutaneous Lidocaine Infusion for Pain in Patients with Cancer.
- Author
-
Seah, Davinia S.E., Herschtal, Alan, Tran, Ha, Thakerar, Arti, and Fullerton, Sonia
- Subjects
- *
CANCER treatment , *CANCER pain , *CONFIDENCE intervals , *LIDOCAINE , *PROBABILITY theory , *SPECIALTY hospitals , *TREATMENT effectiveness , *RETROSPECTIVE studies , *SUBCUTANEOUS infusions - Abstract
Background: Intravenous lidocaine is effective in treating pain. Limited studies have assessed the effectiveness and safety of subcutaneous lidocaine infusions. Methods: We conducted a retrospective review of patients with cancer who received subcutaneous lidocaine infusions for pain. Patient characteristics, pain scores and opioid doses before and after lidocaine, and details of infusions were recorded. We identified three time periods of interest. T0 is defined as the 24-hour period immediately before commencing lidocaine treatment. T1 is defined as the 24-hour period before lidocaine was ceased. T2 is defined as the first 24-hour period after lidocaine was ceased. In addition, the overall impression of the effectiveness of lidocaine was subjectively evaluated by the authors. Results: Twenty patients (13M;7F) received lidocaine. Two patients received it twice, totaling 22 episodes. The median lidocaine dose was 0.67 mg/kg/h with the median duration being 5.5 days. The median worst pain score at T0 and T1 was 8.5 and 5.5, respectively. The difference in the mean pain scores was 3.2 95% CI (2.1, 4.4; p < 0.001). In 15/22 episodes (68%), patients experienced a decrease in pain scores of more than 2. The median morphine oral equivalent (MOE) daily doses at T0, T1, and T2 were 425, 362.5, and 275 mg, respectively. The difference in the mean MOE between T0 and T1 was −126 (95% CI [−281, 28]; p = 0.13). The difference in the mean MOE between T0 and T2 was −207 (95% CI [−370, −44]; p = 0.025). Lidocaine was subjectively deemed effective in 10/22 episodes (45%). There were no documented adverse events attributed to lidocaine. Univariate analyses did not identify any subgroups likely to benefit from lidocaine. Conclusion: Subcutaneous lidocaine infusions may be used safely in cancer pain management and is effective in some patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Assessing Palliative Care Unit Inpatients for Residential Aged Care Placement: Is It Worth It?
- Author
-
Sung, Chee Boon, Johnson, Christina Elizabeth, Lim, Wen Kwang, and Fullerton, Sonia Louise
- Subjects
- *
CONFIDENCE intervals , *EPIDEMIOLOGY , *HEALTH outcome assessment , *PALLIATIVE treatment , *SURVIVAL analysis (Biometry) , *DATA analysis , *RESIDENTIAL care , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Background: Increasing demand for palliative care unit (PCU) admissions has led to a stronger focus on discharge planning. This has resulted in shorter inpatient length of stays (LOS), and stable patients not requiring specialist palliative care services being referred for placement in residential aged care facilities (RACFs). The process of placement is time-consuming and can be distressing to patients and families, so RACF placement should only be proposed in patients whose prognosis is relatively good (i.e., weeks to months). Objective: Our aim was to identify the outcomes of palliative care inpatients referred for residential aged care placement. Methods: A retrospective chart audit was conducted. The patients' outcomes (discharge or death and survival time) were recorded and analyzed using SPSS statistical software. Subjects were 100 consecutive inpatients from a 30-bed PCU who had been referred for RACF placement. Results: Of the 100 patients referred for RACF placement 73 of 100 (73%) patients had a malignant diagnosis, whereas 27 (27%) had a noncancer diagnosis. Thirty-eight (38%) patients died before discharge, including 33 of 73 (45%) patients with cancer and 5 of 27 (13%) patients with nonmalignant conditions. In particular, 12 of 17 (71%) patients with metastatic non-small cell lung (NCSLC) cancer died before or soon after discharge. Conclusion: Over one-third of all patients died before discharge to an RACF could take place. The rate of death before discharge was higher among patients who had cancer. Patients suffering from NCSLC need to be more carefully selected for placement as only one-third of these patients survived to discharge. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.